Amgen today announced results from a pooled posthoc analysis of the pivotal NAVIGATOR Phase 3 and PATHWAY Phase 2b trials showed TEZSPIRE™ (tezepelumab-ekko) demonstrated reductions in the annualized asthma exacerbation rate (AAER) across biomarker subgroups of patients with severe asthma. ...
ConvergeHEALTH Patient Connect™ will serve as the foundation of Amgen’s patient services strategy Deloitte today announced the debut of a global initiative with Amgen to launch an integrated patient services platform powered by ConvergeHEALTH Patient Connect™. The cloud-based, scalable platform will ...
European Commission Approves BLINCYTO® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia Approval Based on Data From the Phase 1/2 ‘205 Study THOUSAND OAKS, Calif., Aug. 29, 2018 – Amgen (NASDAQ:AMGN) today announced that ...